Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 2:28 PM
Ignite Modification Date:
2025-12-25 @ 1:03 PM
NCT ID:
NCT02948959
Group ID:
EG001
Title:
Dupilumab
Description:
Dupilumab 200 mg (in 1.14 mL for \>30 kg BW) or 100 mg (in 0.67 mL for \<=30 kg BW), SC injection q2w for 52 weeks in combination with stable-dose background therapy of medium-dose ICS with a second controller medication (i.e., LABA, LAMA, LTRA or methylxanthines) or high-dose ICS alone or high-dose ICS with second controller medication. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication. Participants were followed up for 12 weeks after last dose (i.e. up to Week 64).
Deaths Number Affected:
0
Deaths Number At Risk:
None
Serious Number Affected:
13
Serious Number At Risk:
271
Other Number Affected:
161
Other Number At Risk:
271
Study:
NCT02948959
Results Section:
NCT02948959
Adverse Events Module:
NCT02948959